Based on data from the February 25, 2021 interim analysis, the probability of success is estimated to be greater than 80% that ADI PEG-20 will demonstrate a statistically significant survival benefit over the control group at the end of the trial. The independent committee conducting the interim analysis recommended proceeding with the Phase III clinical trial according to the protocol without increasing the sample size.